itacitinib   Click here for help

GtoPdb Ligand ID: 8364

Synonyms: Examlpe 294 [WO2011112662] | INCB-039110
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Itacitinib (INCB039110) is a potent and selective inhibitor of Janus kinase 1 (JAK1). Design and synthesis of this compound is claimed in patent WO2011112662 where it is Example 294 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 119.62
Molecular weight 553.2
XLogP 2.28
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(c1F)C(F)(F)F)n1ncc(c1)c1ncnc2c1cc[nH]2
Isomeric SMILES N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(c1F)C(F)(F)F)n1ncc(c1)c1ncnc2c1cc[nH]2
InChI InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
No information available.
Summary of Clinical Use Click here for help
INCB039110 is being assessed in Phase 2 clinical trials as a potential treatment for indications such as rheumatoid arthritis (RA), post essential thrombocythemia myelofibrosis, chronic plaque psoriasis and non-small cell lung cancer (NSCLC). Phase 3 trials in chronic graft-versus-host disease are also underway. Click here to link to's complete list of INCB039110 studies.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
A wide range of cytokines signal via the Janus kinase (JAK) protein tyrosine kinases and signal transducers and activators of transcription (STAT) pathways. Inhibition of the Janus kinases is a highly competitive pharmaceutical field, as these inhibitors show beneficial activity against inflammatory disorders, autoimmune disorders, cancer, and other diseases where cytokine activity is disrupted.